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Abstract
Radiation therapy aims to kill cancer cells with a minimum of normal tissue toxicity. Dying cancer cells have been proposed
to be a source of tumor antigens and may release endogenous immune adjuvants into the tumor environment. For these
reasons, radiation therapy may be an effective modality to initiate new anti-tumor adaptive immune responses that can
target residual disease and distant metastases. However, tumors engender an environment dominated by M2 differentiated
tumor macrophages that support tumor invasion, metastases and escape from immune control. In this study, we
demonstrate that following radiation therapy of tumors in mice, there is an influx of tumor macrophages that ultimately
polarize towards immune suppression. We demonstrate using in vitro models that this polarization is mediated by
transcriptional regulation by NFkB p50, and that in mice lacking NFkB p50, radiation therapy is more effective. We propose
that despite the opportunity for increased antigen-specific adaptive immune responses, the intrinsic processes of repair
following radiation therapy may limit the ability to control residual disease.
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Introduction
There exists an array of cytotoxic therapies that can dramat-
ically reduce the tumor to only a few cells with clonogenic
potential. Unfortunately for cancer patients, tumors can recur
from these small pockets of residual disease. The emergence of
metastases from residual microscopic disease is a major source of
mortality in cancer patients. In animal models of cancer therapy, it
is becoming clear that immune responses play a role in the success
of cytotoxic therapies [1,2,3], and that the outcome following
cytotoxic therapies can be improved by enhancing adaptive
immune responses [1,3,4]. By causing the death of cancer cells,
radiation therapy has been proposed to provide both tumor
antigen and endogenous immune adjuvants to initiate de novo
tumor-specific immune responses.
The majority of cytotoxic cancer therapies result in cancer cell
death through the induction of apoptosis. If the phagocytic
capacity of tumor macrophages is overwhelmed, apoptotic cells
can progress to secondary necrosis and result in induction of pro-
inflammatory cytokines from macrophages [5]. Catastrophic death
of cancer cells can result in release of endogenous immune
adjuvants that can alter immune responses, such as heat shock
proteins, calreticulin and HMGB1 [2,6]. In addition, a range of
studies have demonstrated that it may be possible to select
a cytotoxic agent that promotes immunogenic, non-apoptotic cell
death, or redirects the mechanism of cell death [2,7]. Studies
demonstrate that expression of TLR4, a key receptor for
immunological adjuvants, is critical both for vaccination with
tumor cells killed via radiation or chemotherapy, and the efficacy
of cytotoxic therapy in vivo [8]. These data fit a model where
adjuvants released from dying cancer cells may play a role in
establishing functional anti-tumor immune responses.
Despite the potential immunogenicity of endogenous adjuvants,
the outcome of adjuvant release is heavily influenced by the
differentiation of cells in the environment. Alternative (M2)
activation of macrophages results in a distinct response to adjuvant
compared to classically activated (M1) macrophages. M1 macro-
phages respond to adjuvant with secretion of pro-inflammatory
cytokines such as TNFa, whereas M2 macrophages respond to
adjuvant with secretion of anti-inflammatory cytokines such as IL-
10 [9]. Exposure to apoptotic cells cause macrophages to secrete
a range of anti-inflammatory cytokines, including IL-10 and TGF-
b [5,7,10]. Thus, radiation-induced death of cancer cells may
result in M2 activation via the effect of apoptotic cells, such that
any subsequent release of adjuvants from cancer cells undergoing
secondary necrosis will cause immune suppression. The suppres-
sive response of M2 macrophages is a key feature of inflammatory
resolution, which serves to repair inflammatory destruction
following control of infections by laying down supportive matrix,
establishing vascular structures, and terminating adaptive immune
responses [11,12]. Importantly, these functions are commonly
observed in tumor macrophages, which drive angiogenesis and
adaptive immune suppression in the tumor [13,14,15,16].
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environment during cytotoxic therapies to optimize the contribu-
tion of immune cells to cancer control. We demonstrate that
established tumors display a limited response to radiation therapy
and that treatment is followed by a significant influx of M2-
differentiated macrophages into the tumor stroma. We demon-
strate that NFkB p50 provides a transcriptional mechanism for
polarization of macrophages cells in the presence of irradiated
cancer cells. We demonstrate that in vivo radiation therapy is more
effective in mice defective in M2 polarization though deletion of
NFkB p50. We propose that the polarization of tumor macro-
phages is a limitation for adaptive immune control of residual
disease and may be a target to enhance the efficacy of cytotoxic
therapies.
Materials and Methods
Animals and Cell Lines
The Raw264.7 monocyte/macrophage cell line [17] and the
4T1 mammary carcinoma cell line [18] were obtained from the
ATCC (Manassas, VA). The Panc02 murine pancreatic adeno-
carcinoma cell line [19], (C57BL/6) was kindly provided by Dr
Woo (Mount Sinai School of Medicine, NY). 6–8 week old
C57BL/6 mice and Balb/c were obtained from Charles River
Laboratories (Wilmington, MA) for use in these experiments.
NFkB1
2/2 mice were obtained from The Jackson Laboratory
(Bar Harbor, ME). All animal protocols were approved by the
Earle A. Chiles Research Institute IACUC (Animal Welfare
Assurance No. A3913-01).
Antibodies and Reagents
The FACS antibodies CD11b, Gr1 and IA (MHC class II) were
purchased from Ebioscience (San Diego, CA). Ultrapure LPS was
purchased from Invivogen (San Diego, CA). Western blotting
antibodies used include Arginase I (BD biosciences, San Jose, CA),
iNOS (Cayman Chemical Corporation, Ann Arbor, MI), GAPdH,
anti-mouse-HRP, and anti-rabbit-HRP (all Cell Signaling Tech-
nology, Danvers, MA). Rat anti-F4/80 was purchased from AbD
Serotec (Raleigh, NC), rabbit anti-Von Willebrand Factor (VWF)
was purchased from Abcam, and the secondary antibodies were
anti-Rabbit Alexa Fluor 488 and anti-Rat Alexa Fluor 568
(Invitrogen).
Radiation Therapy of Tumors
Tumors were innoculated s.c. in the right leg below the knee at
a dose of 2610
5 Panc02 or 5610
4 4T1 cells and allowed to
establish for 14–17 days before initiation of treatment. Three daily
20 Gy treatment fractions were given using an Elekta Synergy
linear accelerator (Atlanta, GA) with 6 MV photons with 1 cm
bolus and incorporating a half beam block to minimize dose to the
torso.
Isolation and Analysis of Cancer Cells and Tumor
Infiltrating Cells
For clonogenic analysis of cancer cells, the tumor was dissected
into approximately 2 mm fragments followed by agitation in
1 mg/mL collagenase (Invitrogen), 100 mg/mL hyaluronidase
(Sigma), and 20 mg/mL DNase (Sigma) in PBS for 1 hr at room
temperature. The digest was filtered through 100 mm nylon mesh
to remove macroscopic debris. Serial dilutions of tumor cells were
seeded to 6-well tissue culture plates in media containing 60 mM6 -
thioguanine and colonies were counted after 7 days. The serial
dilution and the colony number were used to calculate the number
of clonogenic cancer cells in the original tumor. For FACS analysis
of tumor infiltrating immune cells, cells suspensions were stained
with antibodies specific for CD11b, IA (MHC class II) and Gr1 as
previously described [20]. The proportion of each infiltrating cell
type was analyzed on a BD LSRII. FACS sorting of tumor
macrophages was performed as previously described [20] using
a BD FACSAria Cell Sorter to greater than 98% purity. The
morphology of the sorted cell populations was determined by
cytospin followed by DiffQuick staining.
Immunohistology
Tumors were fixed in formalin overnight, cyropreserved by
equilibration in 30% sucrose then flash frozen in OCT. 10 mM
cryosections were cut and every 5
th section was H&E stained for
orientation. Neighboring sections were stained with primary
antibodies specific for F4/80 and Von Willebrand Factor (VWF)
and binding detected with Alexa Fluor 488 or Alexa Fluor 568
conjugated secondary antibodies, respectively. Sections were
mounted in the presence of DAPI (Invitrogen, Carlsbad, CA) to
stain nuclear material. Images were acquired using a Zeiss LSM
510-meta confocal microscope at the Oregon Medical Laser
Center.
Gene Expression Microarrays
Total RNA was prepared from FACS sorted CD11b
+IA
+ cells
using a PrepEase RNA Spin Kit (Affymetrix, Cleveland, OH). The
Affymetrix Microarray Core Facility at Oregon Health and
Sciences University (Portland, OR) prepared DNA probes and
performed Microarray Analysis. Gene expression data has been
uploaded to GEO (Accession number GSE34206). Data was
analyzed using GeneSifter (Geospiza Inc, Seattle, WA).
Western Blotting
Cells were lysed in RIPA buffer and denatured in SDS loading
buffer containing b2-mercaptoethanol, electrophoresed on 10%
SDS-PAGE gels and transferred to nitrocellulose. Blocked blots
were probed overnight at 4uC with primary antibodies followed by
HRP-conjugated secondary antibodies. Binding was detected
using a Pierce SuperSignal Pico Chemiluminescent Substrate
(Thermo Fisher Scientific, Rockford, IL) and exposure to film.
Preparation of Bone Marrow Macrophages
Bone marrow cells isolated from long-bones of mice were
cultured for a total of 7 days in complete media containing 40 ng/
ml MCSF (Ebioscience), with additional growth media provided
after 3 days of culture. Adherent cells were harvested and
macrophage differentiation confirmed by flow cytometry for
CD11b, F4/80, Gr1 and IA.
Cancer Cell-macrophage Co-cultures
Panc02 or 4T1 cells were irradiated with a 10 Gy dose using
a cesium source, and 1610
4 cancer cells were co-cultured with
1610
4 Raw264.7 cells or 2610
4 primary bone marrow macro-
phages in replicate wells of 96-well u-bottomed plates for 24 hours
before treatment with 100 ng/ml LPS. Supernatants were
collected after a further 48 hours and tested for cytokine levels
by ELISA using matched antibody pairs specific for TNF and IL-
10 (R&D Systems, Minneapolis, MN) against a standard curve of
recombinant cytokine.
Statistics
Kaplan and Meier survival curves were compared using a log-
rank test. The gene expression phenotypes in each group were
compared using analysis of variance (ANOVA). The difference in
Tumor Macrophages Limit Radiation Therapy
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Student’s T-test.
Results
To investigate the tumor immune environment following
radiation therapy, we developed a model of in vivo radiation
therapy in immunocompetent mice. C57BL/6 mice challenged
s.c. in the leg with Panc02 pancreatic adenocarcinoma were
allowed to establish for 14 days. Mice were then treated with
20 Gy 63 focal radiation to the leg over 3 days. Treatment of the
mouse with the leg extended encompassed the tumor, but the half
beam block ensured rapid dose drop-off and the treatment field
did not include the tumor draining subiliac lymph node. In this
model, radiation therapy had a statistically significant, but limited
effect on the growth of the tumor and on the survival of tumor-
bearing mice. To investigate the efficacy of radiation therapy on
cancer cells, tumors were harvested from mice bearing Panc02
tumors 1 day or 7 days following the final dose of radiation and
cancer cell viability determined by clonogenic assay (Figure 1A).
There was a significant decrease in the clonogenic capacity of the
cancer cells 1 day following the final radiation dose that was
sustained at seven days, while the untreated tumors continued to
grow. These data suggest that the eventual tumor progression
results from an aggressive outgrowth of these residual viable
cancer cells within the post-radiation environment. Macrophages
are a significant component of the tumor environment, and have
an important role in the response to dying cells [5,7,10] and in
directing the repair of damaged tissues [11,12]. To examine the
consequence of radiation-induced cancer cell death on tumor
macrophages, we harvested tumors from mice bearing Panc02
tumors 1 day or 7 days following the final dose of radiation and
performed flow cytometry on tumor-infiltrating cells. The pro-
portion of CD11b
+ cells is significantly increased in tumors 1 day
following the final radiation dose (Figure 1B) and further increased
at 7 days following radiation. This increase in CD11b
+ cells
represents infiltration of multiple myeloid populations into the
tumor. To assess macrophage infiltration, Panc02 tumors were
harvested 7 days following the last dose of radiation and sections
were stained for F4/80
+ macrophages. F4/80
+ macrophages were
found in the stromal area of the untreated tumor and pre-
dominantly clustered around vascular structures (Figure 1C),
though patchy areas of increased macrophage infiltration were
visible when examining the entire untreated tumor (Figure S1).
Following radiation there is an expansion in the stromal area
readily detectible in the H&E staining (Figure 1C, image i-ii),
associated with an increase in F4/80
+ macrophages throughout
the stroma (Figure 1C, image iii-iv). Analysis of the entire tumor
demonstrates that this macrophage infiltration occurs throughout
the treated tumor (Figure S1). These data demonstrate that there is
a significant increase in macrophages in the tumor in response to
radiation therapy and that these macrophages infiltrate into tumor
stroma.
To investigate changes in the phenotype of tumor macrophages
following radiation therapy, we FACS sorted tumor macrophages
from Panc02 tumors (Figure 2). We have previously shown that we
can distinguish mature tumor macrophages from immature
myeloid and MDSC populations by expression of Gr1 and IA
(MHC class II) [20]. To isolate these sub-populations, we first
gated CD11b
+ cells in the untreated or irradiated tumors
(Figure 2A, image i), then sorted the CD11b
+IA
+ macrophage
population and the CD11b
+Gr1
hi MDSC population (Figure 2A,
image ii). Cytospins of the sorted populations demonstrates that
the CD11b
+Gr1
hi MDSC predominantly have a granulocyte
morphology and the CD11b
+IA
+ cells have a macrophage
morphology in both the untreated (Figure 2A, image iii) and
irradiated tumors (Figure 2A, image iv). RNA was purified from
CD11b
+IA
+ macrophages from untreated or irradiated tumors 1
day or 7 days following radiation therapy and Gene Expression
Microarray analysis was performed. The gene expression pattern
confirmed the isolated macrophage phenotype; there was abun-
dant expression of CD14, F4/80, and low or absent expression of
B cell, T cell and endothelial markers (Figure 2B). As has
previously been described for tissue macrophages [21], tumor
macrophages express CD11c [21,22]. Following radiation therapy
expression of CD11c does not change, indicating that there is no
change in potential contaminating dendritic cells (CD11c
+ higher
expression) or neutrophils (CD11c
+ lower expression) and no
dramatic changes in inflammatory stimuli in the tumor [23].
Clustering analysis identified 4 major patterns of gene expression.
Pattern 1 represented genes that were essentially unchanged
between time points, and included the majority of genes. Pattern 2
represented genes that were downregulated at both time points
following radiation, pattern 3 represented genes that were
upregulated immediately following radiation, but declined on
day 7, and pattern 4 represented genes that were upregulated at
day 7. These genes are summarized in Figure S2. Analysis of
regulated genes (Patterns 2–4) by ontology identified predictable
patterns in the regulated genes. Downregulated (pattern 2) genes
included those that were related to proliferation and to cell division
(Figure S2), and this links closely with genes that were upregulated
within a day of radiation (pattern 3), where genes involved in the
response to DNA damage, stress and cell death are highly
represented. Genes upregulated late involved a range of immune
and inflammatory response genes. Since the DNA damage and
anti-proliferative effects of radiation therapy were predicted, we
examined more closely those genes that would not be predicted to
be involved in the direct response to radiation. Following radiation
macrophages downregulate a number of genes involved in
extracellular matrix development, including sparc, a number of
collagen genes (col1a1, col1a2, col3a1, col6a1) and biglycan (bgn)
(Figure S2, image i), suggesting that macrophage support of stroma
may be transiently suspended following radiation therapy.
Amongst those genes transiently upregulated following radiation,
macrophages upregulate ccl2 and ccl7 (Figure S2, image ii), each of
which have been associated with recruitment of macrophages to
infectious and wound sites via the receptor CCR2 [24,25]. At this
day 1 post-radiation time point, there is possible evidence of a pro-
inflammatory macrophage response, as indicated by upregulation
of cd80, tnfsf9 (41BBL) and tnf, though expression of these genes
declines by day 7 post-radiation. Interestingly, at the day 1 time-
point, there is upregulation of mertk and gas6, key genes mediating
macrophage phagocytosis of dying cells [26]. By 7 days following
radiation, we see upregulation of ccr2 (Figure S2, image iii), which
may represent chemotaxis in response to earlier upregulation of
ccl2 and ccl7. In addition, at this time point macrophages
upregulate tlr2 and tlr4, potentially indicating heightened re-
sponsiveness to endogenous adjuvants released by dying cells. It is
of note that ccr2, tlr2 and tlr4, along with cd43, are the genes
causing a high Z-score for the tumor necrosis factor biosynthetic
process ontologies at day 7 following radiation (Figure S2, image
iii). These changes suggest that significant inflammatory changes
in tumor macrophages occur following radiation therapy that may
influence the tumor environment.
Despite these fluctuations in gene expression, the tumor
macrophages maintain or increase a polarized M2 phenotype,
shown by their expression of M1 and M2 macrophage markers
(Figure 2C) as defined by Murray and Wynn [22]. Importantly,
Tumor Macrophages Limit Radiation Therapy
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express substantial levels of the M2 marker arginase I, which
significantly increases following radiation therapy (Figure 2C) and
has been shown to inhibit T cell function [16,27]. To validate the
microarray data, we FACS sorted CD11b
+IA
+ and CD11b
+Gr1
hi
populations from Panc02 tumors 7 days following radiation
therapy, or from tumors left untreated, and prepared protein
lysates from purified cells. Western blotting of these lysates
demonstrated increased expression of arginase I in macrophages
following radiation therapy, and undetectable expression of iNOS
(Figure 2C, image ii). To confirm the lack of iNOS expression in
tumor macrophages, we sorted CD11b
+IA
+ and CD11b
+Gr1
hi
populations from 4T1 tumors and western blotted these lysates
alongside lysates of Raw264.7 macrophages cultured alone or with
irradiated 4T1 cells (Figure S3). In these experiments, CD11b
+IA
+
tumor macrophages, but not CD11b
+Gr1
hi tumor neutrophils
express arginase I and neither population expresses detectible
iNOS. Importantly, Raw264.7 macrophages decrease their iNOS
expression and increase Arginase I expression, indicating a shift
from M1 to M2 phenotype. These data indicate while there may
be an initial shift towards pro-inflammatory macrophage activa-
tion as indicated by TNFa and CD80 upregulation, macrophages
within the tumor retain M2 differentiation and that by day 7
following radiation the pro-inflammatory window has resolved.
The tumor environment 7 days following radiation may be more
suppressive to adaptive immune responses due to the increased
number of M2 macrophages with increased expression of arginase
I.
These data imply that it is these M2-differentiated macrophages
that will be exposed to any immunological adjuvants that are
released from dying cancer cells following radiation therapy. To
evaluate the response of tumor macrophages to adjuvants, we
Figure 1. Radiation therapy of tumors. a) C57BL/6 mice were challenged with 2610
5 Panc02 s.c. in the right leg and mice received 3 daily doses
of 20 Gy focal radiation to the leg beginning on day 14 (RT) or were left untreated (NT). i-ii) 1 day or iii-iv) 7 days following the final radiation dose,
tumors were harvested, digested and clonogenic assays performed. b) One and seven days following the final radiation dose, tumors were harvested
and tumor-infiltrating cells determined by FACS analysis. Graphs show the mean and standard error of tumor infiltrating CD11b
+ cells in Panc02
tumors, and include data from two replicate experiments. c) Panc02 tumors were harvested for histology 7 days following the final radiation dose.
Images show representative regions of neighboring sections from tumors receiving NT (i & iii) or RT (ii & iv) that were i-ii) H&E stained or iii-iv)
underwent immunofluorescence staining with antibodies specific for VWF and F4/80, and detected with antibodies conjugated to AF488 (Green) and
AF568 (Red), respectively. Nuclear material was counterstained with DAPI (Blue) and sections were imaged by confocal microscopy.
doi:10.1371/journal.pone.0039295.g001
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+IA
+ tumor macrophages from untreated
4T1 or Panc02 tumors and measured their cytokine response to
LPS stimulation. Stimulation of purified CD11b
+IA
+ cells with
LPS causes secretion of IL-10, but not TNFa (Figure 3A). To
investigate whether newly recruited macrophages would be
polarized in the tumor environment following radiation therapy,
we incubated bone marrow-derived macrophages alone, with live
4T1 cancer cells or with irradiated 4T1 cancer cells for 24 hours
before stimulation with LPS. Co-culture with irradiated cancer
cells increased IL-10 secretion following LPS stimulation
(Figure 3B, image i). Similarly, Raw264.7 monocyte/macrophages
are only polarized to produce IL-10 following co-culture with
Figure 2. Gene expression microarray of tumor macrophages following radiation. a) Panc02 tumors were harvested 1 and 7 days following
the final radiation dose and i) gated CD11b
+ cells were FACS sorted according to expression of ii) Gr1 and IA. Sorted populations of CD11b
+Gr1
hi and
CD11b
+IA
+ cells from iii) NT or iv) RT tumors were tested for morphology by cytopsin and Diff-Quik staining. RNA was prepared from sorted
CD11b
+IA
+ cells and Affymetrix gene expression microarray analysis was performed. Gene expression profiles were analyzed for the expression of b)
lineage markers and c) M1 and M2-associated markers. d) CD11b
+Gr1
hi and CD11b
+Gr1
lo cells were sorted as in a) and lysates prepared from sorted
cells for western blotting. The image represents 3 western blots cropped and positioned above each other to show detection of Arginase I, iNos and
GAPDH. Gene array analysis uses RNA collected from purified macrophages isolated in 2 replicate experiments. Each gene list is sorted by gene
expression level and includes an individual key showing the gene intensity scale for that group.
doi:10.1371/journal.pone.0039295.g002
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demonstrate that tumor-associated macrophages are polarized
towards an M2 phenotype, and that dying cancer cells generated
by radiation therapy may cause M2 polarization of newly
recruited macrophages.
Endogenous T cell responses play a significant role in tumor
control by radiation therapy, but are generally insufficient to cure
tumors in the absence of additional immunotherapy [1,3,4]. A
number of investigators have characterized a transient improve-
ment in the immune environment of the tumor following radiation
therapy [28,29]; however, our data suggests that tumor macro-
phages will work against adaptive immune cells by release
immunosuppressive cytokines in response to endogenous adju-
vants. For these reasons we hypothesized that preventing
macrophages from becoming M2 and suppressing adaptive
immunity would improve the efficacy of radiation therapy.
Classically, pro-inflammatory TNFa gene expression in response
to TLR ligation occurs via signal transduction incorporating
NFkB heterodimers. To investigate whether NFkB p50 was
involved in redirection of the macrophage response, we prepared
bone marrow macrophages from wild-type mice or from NFkB1
knockout mice that are deleted for the p105 precursor protein of
NFkB p50. We demonstrate that in the presence of irradiated 4T1
cells, bone marrow macrophages from wild-type mice secrete IL-
10 in response to LPS stimulation, while NFkB1 knockout mice
secrete TNFa (Figure 4). As seen in purified tumor macrophages
(Figure 3A) cytokine production following co-culture is dependent
on LPS stimulation, indicating that dying cells provide a differen-
tiation signal with macrophage polarization becoming evident
following stimulation. These data demonstrate macrophage de-
viation to IL-10 production requires the transcriptional activity of
NFkB p50.
To determine the consequence of redirected macrophage
polarization in vivo, we established Panc02 tumors in wild-type or
NFkB1 knockout mice and treated these mice with radiation
therapy. Despite radiation therapy, all tumors eventually recur in
wild-type mice (Figure 5A). However, in NFkB1 knockout mice,
tumors are controlled by radiation. Survival in mice bearing
Figure 3. Cytokine responses of tumor macrophages. a) CD11b
+IA
+ cells were sorted from i) 4T1 tumors or ii) from Panc02 tumors and treated
in vitro with 100 ng/ml LPS, or left untreated (NT). 24 hours later supernatants were collected and ELISA tested for secretion of IL-10 and TNFa.b )i )
Bone marrow-derived macrophages were incubated alone or with untreated or irradiated 4T1 cancer cells for 24 hours before stimulation with
100 ng/ml LPS. Supernatants were collected and ELISA tested for secretion of IL-10 and TNFa after a further 48 hours. ii) Raw264.7 macrophages were
incubated alone or with an equal number of untreated or irradiated 4T1 cancer cells (10 or 20 Gy) for 24 hours, then treated with 100 ng/ml LPS and
supernatants collected and ELISA tested for secretion of IL-10 after a further 48 hours. Graphs are representative of multiple replicate experiments.
doi:10.1371/journal.pone.0039295.g003
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knockout mice, but is significantly different following radiation
therapy (wtNT vs. wtRT p,0.001; wtNT vs. NFkB1
2/2NT NS;
NFkB1
2/2NT vs. NFkB1
2/2RT p,0.005; wtRT vs. NFkB1
2/
2RT p,0.001) (Figure 5B). To determine whether tumor
treatment resulted in endogenous immune protection, surviving
mice were rechallenged with Panc02 or irrelevant 3LL tumors.
Both Panc02 and 3LL grew in naı ¨ve NFkB1
2/2 mice. NFkB1
2/2
mice that were cleared of their primary tumor by radiation therapy
were protected against rechallenge with Panc02 tumors, but
remained susceptible to 3LL tumors (Figure 5C). These data
demonstrate that mice bearing Panc02 tumors that were cleared by
radiation therapy also developed an endogenous tumor antigen-
specific response and long-term protective immunity to the primary
tumor. Together, these data support the hypothesis that tumor
macrophage polarization limits the efficacy of radiation therapy,
and demonstrate that expression of NFkB1 limits the efficacy of
radiation therapy in vivo.
Discussion
These data demonstrate that tumors can recur despite
significant reductions in the clonogenic potential of cancer cells
following hypofractionated radiation therapy (Figure 1). Treat-
ment failure is associated with an influx of macrophages into the
tumor site (Figure 1) that exhibit an immune suppressive and M2
phenotype by 7 days post radiation treatment (Figure 2). We
demonstrate that adjuvant causes M2 polarized macrophages in
the tumor to secrete the immune suppressive cytokine IL-10
(Figure 3), and that that polarization of macrophages by dying
cancer cells occurs through a transcriptional switch via regulation
of NFkB p50 (Figure 4). The consequence is that radiation therapy
is more effective in mice deficient in NFkB p50 (Figure 5). These
data demonstrate that the established tumor environment is not
optimal for adaptive immunity, and that while cytotoxic therapy
may release tumor antigens and endogenous adjuvants, the
consequence may be further antigen-specific immune suppression
at the tumor site. It is important to note that while the untreated
tumor has M2 differentiated macrophages, immediately following
radiation therapy there may be a transient upregulation of M1
signals that resolves as the tumor transitions to repair. However,
while the macrophages recruited to the tumor following radiation
therapy would not be expected to be pre-polarized to either M1 or
M2 phenotypes, they enter an environment already populated
with M2 macrophages and on entry the newly recruited
macrophages are able to interact with dying cells. That the
expression of M2 markers is sustained or increases following
radiation therapy suggests that the irradiated tumor environment
drives M2 differentiation of these newly recruited cells. The result
is M2 differentiation of both new and existing tumor macrophages.
Radiation alone rarely results in tumor-specific immunity capable
of destroying untargeted tumors – the elusive abscopal effect.
However, immunotherapy in combination with radiation therapy
have shown abscopal activity in animal models [4]. It is possible
that well-timed T cell targeted immune interventions can over-
come the negative environment, for example by increased
infiltration of the tumor by T cells that produce inflammatory
cytokines [20]. The experiments described here suggest that
alternative therapeutic interventions targeting macrophage differ-
entiation will be complimentary and can be exploited to optimize
adaptive immune control of residual disease.
These data have implications for the integration of radiation
therapy and immunotherapies in the clinic. While many
immunotherapies are effective in animal models, their success
commonly depends on treatment very early in tumor develop-
ment. In transplantable tumor models it takes at least 10 days to
establish a suppressive environment made up of suppressive
macrophages and regulatory T cells [30,31]. Potent immunother-
apeutic antibodies are no longer effective if tumors have time to
establish their immune suppressive environment beyond 10 days
[20,32,33]. This scenario is relevant for treatment of cancer
patients since tumors accumulate an array of immune regulatory
features as part of their evolution into clinically relevant
malignancies. Despite the increased immune suppression that we
describe following radiation, there may be a transient window of
classical inflammation in the tumor before inflammatory resolu-
tion is established and the tumor is repaired. Over the course of
radiation, patients have been shown to develop tumor antigen-
specific immune responses that were not detectable before
treatment [34]. In addition, in animal models, radiation therapy
is less effective if endogenous CD8 T cell responses are eliminated
[1,3]. Radiation has been shown to render the tumor site
transiently more attractive to effector T cells [28,29] and the
combination of radiation with multiple infusions of tumor-specific
effector T cells can combine to alter the wound repair phenotype
of the tumor providing an extended mechanism of tumor control
[35]. Thus, in the face of an established, suppressive tumor it may
Figure 4. NFkB in macrophage polarization. a) Macrophages were derived from the bone marrow of wild-type (wt) or NFkB1
2/2 mice and
incubated alone or with 10 Gy irradiated 4T1 cancer cells for 24 hours, then treated with 100 ng/ml LPS and ELISA tested for secretion of i) TNFa and
ii) IL-10 after a further 48 hours.
doi:10.1371/journal.pone.0039295.g004
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immune control of residual disease.
The specific roles of the classical M1 cytokine TNFa as opposed
to the M2 cytokine IL-10 response is not clear; each cytokine may
simply be an indicator of broader macrophage differentiation.
However, TNFa has been shown to inhibit tumor angiogenesis
[36], synergize with radiation therapy [37], and a spike in serum
TNFa was associated with one documented case of abscopal
tumor regression [38]. By contrast, IL-10 feeds back on
macrophages to increase alternative macrophage differentiation
[39], and the progressive induction of IL-10 in tumor infiltrating
cells during tumor growth has been shown to suppress anti-tumor
adaptive immune responses [40]. IL-10 can be effectively blocked
with specific antibodies to the cytokine and to the IL-10 receptor,
and blockade of IL-10 has been shown to result in more effective
immune control of tumors [41].
The experiments described here identify tumor macrophages as
potential therapeutic targets to increase immune control of
residual disease following radiation therapy. In animal models,
local control by radiation therapy has been improved by
preventing macrophage influx following radiation by total body
irradiation [42] or by antibodies specific to Mac-1 [43]. Rather
than depleting macrophages, it has also been proposed that
interfering with the polarization of tumor macrophages is
a potential therapeutic strategy [44]. While this study focuses on
the contribution of macrophage polarization to tumor control by
radiation therapy, the ubiquity of NFkB in transcriptional
regulation means that other cell types may play a role in the
outcome of the in vivo radiation therapy experiments. Ongoing
work in the laboratory aims to identify he contribution of other
cells, such as T cells and endothelial cells in NFkB1 deficient mice.
The accumulation of NFkB p50 and the formation of
transcriptionally regulatory p50 homodimers appear to play an
important role in the resolution of inflammation. While clearance
of bacterial infections is not altered by the absence of NFkB1,
NFkB p50 deficient mice exhibit excessive and prolonged
inflammation following bacterial clearance [45], and the conse-
quence of inflammatory injuries is more severe in the absence of
NFkB p50 [46]. Saccani et al. demonstrated that macrophages
isolated from tumors have increased expression of NFkB p50, and
accumulate NFkB p50 homodimers in the nucleus [47]. NFkB
p50 homodimers can bind to the same NFkB sites in the TNFa
promoter as conventional NFkB heterodimers, but result in
transcriptional inhibition rather than transcriptional activation
[48]. By contrast, the same complexes promote transcription of IL-
10 [48]. Our data showing that NFkB p50 deficient macrophages
Figure 5. Radiation therapy of tumors in NFkB1 knockout mice. a) Wild-type (wt) or NFkB1
2/2 C57BL/6 mice were challenged with 2610
5
Panc02 s.c. in the right leg and mice received 3 daily doses of 20 Gy focal radiation to the leg beginning on day 14 (RT) or were left untreated
(NT).Tumor leg diameter was measured 36per week. b) Survival curves of mice in a replicate experiment treated as in a) where mice were euthanized
at a leg diameter exceeding 12 mm. c) Proportion of tumors growing following s.c. injection of 3LL or Panc02 in NFkB1
2/2 naı ¨ve mice or NFkB1
2/2
mice that were cured of their primary tumor with radiation therapy (RT).
doi:10.1371/journal.pone.0039295.g005
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cancer cells is consistent with data from Saccani et al. with M2
tumor macrophages [47], and interestingly also with data from
Porta et al. with tolerized macrophages [49]. It is interesting that
tolerized macrophages closely resemble M2 macrophages
[49,50,51], and it is possible that M1 and M2 differentiation
may be temporally regulated in addition to regulation via
inflammatory mediators and regulatory cytokines [52]. Our data
fits a model where the tumor environment post-cytotoxic therapy
is a site of inflammatory resolution, and we propose that this
process of inflammatory resolution is part of an endogenous
process of repair that can protect the tumor site for eventual
recurrence. In the response to infections or following administra-
tion of sterile irritants, preventing immune resolution results in
increased pathology. Thus, we propose that sustaining M1
differentiation, or creating a non-resolving environment in the
tumor will increase destruction at the inflammatory site. In cancer
therapy, increased destruction at a focused target site could be
considered a benefit.
Supporting Information
Figure S1 Margin to margin overview of tumor histol-
ogy following radiation therapy. C57BL/6 mice were
challenged with 2610
5 Panc02 s.c. in the right leg and mice
received 3 daily doses of 20 Gy focal radiation to the leg beginning
on day 14 (RT) or were left untreated (NT). Tumors were
harvested for histology 7 days following the final radiation dose.
Images show neighboring sections from tumors receiving NT or
RT that were H&E stained or underwent immunofluorescence
staining with antibodies specific for VWF and F4/80, and detected
with antibodies conjugated to AF488 (Green) and AF568 (Red),
respectively. Nuclear material was counterstained with DAPI
(Blue) and sections were imaged by confocal microscopy. Multiple
digital images were taken from the tumor margin to the opposite
margin and digitally stitched to recreate a margin-to-margin
overview of a representative tumor.
(TIF)
Figure S2 Cluster analysis was performed using Gene-
sifter software to identify four patterns of gene expres-
sion. Gene expression Pattern 1 was little changed between
samples. Within gene expression Pattern i) 2, ii) 3, and iii) 4, only
those genes characterized as present and that demonstrate
significant differences in gene expression (ANOVA) were included
in ontology analysis (top). Groups are sorted by Z-score. Gene lists
within these clusters (bottom) are limited to those showing
significant differences in gene expression (ANOVA) and greater
than 1.5 fold changes in gene expression. Final gene lists are sorted
by peak expression and the top 80 genes are shown (where
sufficient numbers matching these criteria are present), separated
into groups of 20 genes per column with an individual key showing
the gene intensity scale for that group.
(TIF)
Figure S3 Macrophage polarization from iNOS to
Arginase expression by irradiated cancer cells a) Tumor
infiltrating cells from 4T1 tumors were harvested and i) gated
CD11b
+ cells were FACS sorted according to expression of Gr1
and IA. Sorted populations of ii) CD11b
+Gr1
hi and iii)
CD11b
+IA
+ cells were used to prepare protein lystates. a) Western
blot of protein lysates from sorted tumor myeloid cells (lanes 3 and
4) alongside lysates from Raw264.7 macrophages incubated alone
or with equal numbers of irradiated 4T1 cells (lanes 1 and 2).
Lanes were loaded with equal protein and probed with antibodies
specific for Arginase I, iNOS and GAPdH. The image represents 3
western blots cropped and positioned above each other to show
detection of Arginase I, iNos and GAPDH.
(TIF)
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